“As part of this agreement, Cipla will be responsible for distribution of the COVID-19 rapid antibody kit that will be manufactured by MultiG” the company added.
MultiG’s rapid antibody kit is marketed under the brand name ‘Covi-G‘.
Cipla said MultiG rapid antibody kit has been commercialised in over 20 countries already, with sensitivity and specificity exceeding 92 per cent.
Cipla said its expansive reach, network and partnerships with public health authorities as well as private institutions will help in ensuring the seamless access of these kits across over 25 markets in Asia, Middle-East and North Africa, Latin America, EU and Australia.
Shares of Cipla were trading 0.20 per cent lower at Rs 741 apiece on BSE.